CORDIS · HTx
Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe
- Code
HTx- Programme
- H2020
- Call
SC1-BHC-26-2018- Status
- CLOSED
- Period
- 2019-01-01 – 2024-06-30
Official data · CORDIS · synced 2026-10-17 10:16 · official record
Participants
| Organisations | Role | Country | Grant |
|---|---|---|---|
| UNIVERSITEIT UTRECHT | coordinator | NL | 1 352 135 € |
| UNIVERSITY OF YORK | participant | UK | 984 602 € |
| ORGANISATION EUROPEENNE POUR LA RECHERCHE ET LE TRAITEMENT DU CANCER AISBL | participant | BE | 862 250 € |
| NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE | participant | UK | 839 398 € |
| UNIVERSITAET BERN | participant | CH | 749 062 € |
| SYNAPSE RESEARCH MANAGEMENT PARTNERS SL | participant | ES | 726 688 € |
| OULUN YLIOPISTO | participant | FI | 726 500 € |
| SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG | participant | HU | 679 162 € |
| EURORDIS - RARE DISEASES EUROPE | participant | FR | 625 908 € |
| ZORGINSTITUUT NEDERLAND | participant | NL | 484 450 € |
| UNIVERSITEIT MAASTRICHT | participant | NL | 384 855 € |
| UNIVERSIDAD POLITECNICA DE MADRID | participant | ES | 382 100 € |
| МЕДИЦИНСКИ УНИВЕРСИТЕТ | participant | BG | 313 688 € |
| TANDVARDS-OCH LAKEMEDELSFORMANSVERKET | participant | SE | 301 852 € |
| KOBENHAVNS UNIVERSITET | participant | DK | 228 125 € |
| ACADEMISCH ZIEKENHUIS GRONINGEN | third party | NL | 0 € |
| UNIVERSITAIR MEDISCH CENTRUM UTRECHT | third party | NL | 0 € |
Description
HTx will create a framework for next generation Health Technology Assessment (HTA) that supports patient-centred, societally oriented, and real-time decision-making for integrated healthcare throughout Europe. HTx will focus on therapeutic areas with high unmet need for which HTA information has to be provided on complex and personalised combinations of health technologies. Based on a select number of relevant case studies, HTx will enhance methods for integrating evidence from RCTs and real-world data (RWD). HTx will also augment statistical and econometric methods for generating robust estimates of effectiveness and cost-effectiveness in order to support relevant HTA decision-making for these complex and personalised combinations of health technologies. HTx will also contribute to improving methods to support personalised treatment advice fitted for sharing with patients and their physicians. This includes the development of statistical and econometric approaches and artificial intelligence/machine learning methods for forecasting treatment effects in specific groups of patients. Simultaneously, in close collaboration with the European Network for HTA (EUnetHTA), HTx will improve synergies between regulatory agencies, HTA bodies and clinical guideline developers. This will include the translation of HTx methods into already existing European guidelines, most prominently those developed by EUnetHTA. HTx will also support initial efforts to discuss reimbursement and funding models that facilitate controlled access to and the pricing of these complex health technologies. Finally, we will evaluate the transferability of HTx results into all EU Member Countries especially in Central and Eastern European (CEE) Countries and promote the dissemination of HTx results to the different European stakeholders with a special focus on the patient community.
Official data · CORDIS · synced 2026-10-17 10:16 · official record · Licence: © European Union, CC BY 4.0 (Commission reuse policy).